Corbus Pharmaceuticals Holdings, Inc.

NASDAQ•CRBP

CEO: Dr. Yuval Cohen Ph.D.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2014-10-27

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Contact Information

500 River Ridge Drive, Norwood, MA, 02062, United States

617-963-0100

www.corbuspharma.com

Market Cap

$119.21M

P/E (TTM)

-1.6

17.5

Dividend Yield

52W High

$20.56

52W Low

$4.64

52W Range

31%

Rank65Top 96.0%

1.6

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 1.6 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$0.00+0.00%

4-Quarter Trend

EPS

-$1.25+0.00%

4-Quarter Trend

FCF

-$15.93M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

CRB-701 Clinical Advancement CRB-701 data presented at ESMO25; FDA meeting planned Q1 2026 for HNSCC/cervical registration.

CRB-913 Obesity Trial Progress Phase 1a completed; Phase 1b CANYON-1 study initiated December 2025, completion expected Summer 2026.

R&D Spending Increased 118% R&D expense reached $70.1M USD in 2025, up 118% from $32.2M USD, focusing on pipeline advancement.

Cash Position Maintained Total cash, equivalents, investments stood at $163.3M USD as of December 31, 2025, supporting operations.

Risk Factors

Net Loss Significantly Widened Net loss reached $78.5M USD in 2025, substantially increasing from $40.2M USD loss in prior year.

Continued Need for Capital Expect continued operating losses; substantial additional financing required to fund ongoing pre-clinical and clinical development.

Reliance on Third-Party Manufacturing Complete dependence on contract manufacturers for cGMP supply; failure risks halting development or commercialization efforts.

CRB-601 Program Deprioritized CRB-601 program deprioritized; company will not enroll additional patients in the Phase 1 dose escalation study.

Outlook

Advance CRB-701 Regulatory Path Expect meeting with FDA in Q1 2026 to discuss clinical data and registrational study protocols for CRB-701.

Complete CRB-913 Phase 1b Study CANYON-1 Phase 1b dose-range finding study completion expected in Summer 2026 for obesity candidate.

Manage Operating Cash Runway Current cash ($163.3M USD) expected to fund operations for at least twelve months from filing date.

Maintain Nasdaq Listing Compliance Must satisfy Nasdaq continued listing requirements; failure risks delisting, impairing liquidity and financing ability.

Peer Comparison

Revenue (TTM)

GNFT

$126.71M

+9.8%

CDXS

$70.39M

+18.6%

IVVD

$53.43M

+110.5%

Gross Margin (Latest Quarter)

GNFT

100.0%

+0.0pp

SGMO

100.0%

+0.0pp

APLT

100.0%

+0.0pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
GNFT	$445.68M	-11.0	-63.7%	64.1%
PEPG	$369.77M	-2.5	-75.7%	9.8%
FBRX	$343.99M	-9.4	-75.6%	0.0%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:May 4, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data